^
    1d
    MP0533-CP101: Study of MP0533 in Patients Acute Myeloid Leukemia or Myelodysplastic Syndrome (clinicaltrials.gov)
    P1/2, N=249, Active, not recruiting, Molecular Partners AG | Recruiting --> Active, not recruiting | Trial completion date: Dec 2029 --> May 2027 | Trial primary completion date: Dec 2027 --> May 2026
    Enrollment closed • Trial completion date • Trial primary completion date • First-in-human
    |
    Venclexta (venetoclax) • azacitidine • Gazyva (obinutuzumab) • MP0533
    9d
    TP53 deficiency in AML induces resistance to T-cell engagers through an immunosuppressive secretome. (PubMed, Leukemia)
    Cytotoxicity against TP53-deleted (DEL) primary AML cells and TP53-knockdown (KD) AML cell lines was reduced in co-cultures with T cells stimulated with the BiTE molecule AMG 330 (CD3×CD33)...RNA sequencing of T cells co-cultured with TP53 KD cells uncovered a transcriptional shift toward a senescent cell cycle profile. Our data collectively identify the immunosuppressive secretome of TP53-deficient AML as a key barrier to T-cell-engaging immunotherapies, underscoring an unmet clinical need for strategies able to restore T-cell function in TP53 KD AML.
    Journal • IO biomarker
    |
    TP53 (Tumor protein P53) • CD33 (CD33 Molecule) • TGFB1 (Transforming Growth Factor Beta 1)
    |
    TP53 mutation
    |
    eluvixtamab (AMG 330)
    1m
    A Study of JNJ-89853413 for Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Neoplasms (clinicaltrials.gov)
    P1, N=64, Active, not recruiting, Janssen Research & Development, LLC | Recruiting --> Active, not recruiting | N=115 --> 64
    Enrollment closed • Enrollment change • First-in-human
    4ms
    Testing the Combination of Anti-cancer Drugs Actimab-A and Cemiplimab (REGN2810) to Improve Outcomes for Patients With Recurrent Glioblastoma (clinicaltrials.gov)
    P1, N=30, Not yet recruiting, National Cancer Institute (NCI)
    New P1 trial • Tumor mutational burden • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • MGMT (6-O-methylguanine-DNA methyltransferase) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4)
    |
    IDH wild-type • IDH1 R132
    |
    Libtayo (cemiplimab-rwlc) • Actimab-A (lintuzumab-Ac225) • Zamyl (lintuzumab)
    4ms
    Natural Killer(NK) Cell Therapy in Acute Myeloid Leukemia (clinicaltrials.gov)
    P1, N=2, Completed, Institute of Hematology & Blood Diseases Hospital, China | Not yet recruiting --> Completed | N=102 --> 2
    Trial completion • Enrollment change • First-in-human
    |
    CD33 (CD33 Molecule)
    |
    CD33 positive
    |
    cytarabine • fludarabine IV • CD33/CLL1 dual CAR-NK cell • Super NK cell therapy
    5ms
    A Study of JNJ-89853413 for Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Neoplasms (clinicaltrials.gov)
    P1, N=100, Recruiting, Janssen Research & Development, LLC | Trial completion date: Aug 2028 --> Jan 2028
    Trial completion date • First-in-human
    1year
    Study of CC-96191 in Participants With Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov)
    P1, N=45, Terminated, Celgene | N=80 --> 45 | Active, not recruiting --> Terminated; Business objectives have changed
    Enrollment change • Trial termination
    over1year
    Study of CC-96191 in Participants With Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov)
    P1, N=80, Active, not recruiting, Celgene | Recruiting --> Active, not recruiting
    Enrollment closed
    over1year
    STING activation improves T-cell-engaging immunotherapy for acute myeloid leukemia. (PubMed, Blood)
    We established a key role for IFNγ in AMG 330-mediated cytotoxicity against AML cells, and in rendering AML cells responsive to STING agonism. Here, we propose to improve the efficacy of CD33-targeting BsAbs by combining them with a STING agonist.
    Journal
    |
    IFNG (Interferon, gamma) • TNFA (Tumor Necrosis Factor-Alpha) • CD33 (CD33 Molecule) • STING (stimulator of interferon response cGAMP interactor 1)
    |
    Actimmune (interferon gamma-1 b) • eluvixtamab (AMG 330)
    over1year
    HM2023-05: GTB-3650 Trike for High Risk MDS and R/R AML (clinicaltrials.gov)
    P1, N=45, Recruiting, Masonic Cancer Center, University of Minnesota | Trial completion date: Nov 2029 --> Oct 2027 | Trial primary completion date: Nov 2028 --> Mar 2027
    Trial completion date • Trial primary completion date
    |
    GTB-3650
    over1year
    HM2023-05: GTB-3650 Trike for High Risk MDS and R/R AML (clinicaltrials.gov)
    P1, N=45, Recruiting, Masonic Cancer Center, University of Minnesota | Not yet recruiting --> Recruiting
    Enrollment open • Trispecific
    |
    GTB-3650
    over1year
    Natural Killer(NK) Cell Therapy for Acute Myeloid Leukemia (clinicaltrials.gov)
    P1, N=3, Terminated, Institute of Hematology & Blood Diseases Hospital, China | N=18 --> 3 | Recruiting --> Terminated; It did not reach the expected results of clinical trial
    Enrollment change • Trial termination
    |
    CD33 (CD33 Molecule)
    |
    CD33 positive
    |
    cytarabine • fludarabine IV • QN-023a